Fantastic results presented by Matthew Renfrow! 🔥
🔛 The bidirectional influence between Gd-IgA1 and kidney outcomes!
tobias-b-huber.bsky.social CureGN
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
Fantastic results presented by Matthew Renfrow! 🔥
🔛 The bidirectional influence between Gd-IgA1 and kidney outcomes!
tobias-b-huber.bsky.social CureGN
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
🌟 Fantastic talk by Abigail Smith!
👉 The promising role of eGFR and proteinuria as surrogate markers in APOL1 kidney disease
tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
🌟 Fantastic talk by Abigail Smith!
👉 The promising role of eGFR and proteinuria as surrogate markers in APOL1 kidney disease
tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
Which trial is best for which disease and context? 🔎
tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #ClinicalTrials #NephTwitter #Nephrology
Which trial is best for which disease and context? 🔎
tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #ClinicalTrials #NephTwitter #Nephrology
🔜 Multi-arm trials and trial platforms are much needed in #GlomerularDisease!
🐙 Should we call them octopus or even 'podocyte' trials?
tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #ClinicalTrials #NephTwitter #Nephrology
🔜 Multi-arm trials and trial platforms are much needed in #GlomerularDisease!
🐙 Should we call them octopus or even 'podocyte' trials?
tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #ClinicalTrials #NephTwitter #Nephrology
Hey #Nephtwitter!
Welcome to a 🆕 #tweetorial #xtorial brought to you by @KIReports
🦠 Today, we're exploring BK polyomavirus-specific immunity and viral clearance after kidney transplantation. VA by @mdabdulqader83.bsky.social
Hey #Nephtwitter!
Welcome to a 🆕 #tweetorial #xtorial brought to you by @KIReports
🦠 Today, we're exploring BK polyomavirus-specific immunity and viral clearance after kidney transplantation. VA by @mdabdulqader83.bsky.social
Visit GNpredict.com to access evidence-based prediction tools 💥
tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
Visit GNpredict.com to access evidence-based prediction tools 💥
tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
Timothy Niewold brilliantly uncovering current trials and emerging therapis targeting innate immune pathways in #GlomerularDisease
#CTS2026 #ISGD #ClinicalTrials #NephTwitter #Nephrology
tobias-b-huber.bsky.social
Timothy Niewold brilliantly uncovering current trials and emerging therapis targeting innate immune pathways in #GlomerularDisease
#CTS2026 #ISGD #ClinicalTrials #NephTwitter #Nephrology
tobias-b-huber.bsky.social
Jonathan Hogan finishing this fantastic table with cellular therapy and bispecific antibodies for #GlomerularDisease 🔥
Impressive results, distinct toxicities, potential cure? 🔎
#CTS2026 #ISGD #ClinicalTrials #NephTwitter #Nephrology
tobias-b-huber.bsky.so
Jonathan Hogan finishing this fantastic table with cellular therapy and bispecific antibodies for #GlomerularDisease 🔥
Impressive results, distinct toxicities, potential cure? 🔎
#CTS2026 #ISGD #ClinicalTrials #NephTwitter #Nephrology
tobias-b-huber.bsky.so
Alexander Duncan revolutionizing talk about targeting suPAR with the new monoclonal antibody WAL0921 💫
Promising early clinical results! 🚀🔜
#CTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
tobias-b-huber.bsky.social
Alexander Duncan revolutionizing talk about targeting suPAR with the new monoclonal antibody WAL0921 💫
Promising early clinical results! 🚀🔜
#CTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
tobias-b-huber.bsky.social
Laura Mariani brilliantly discussed how biomarkers can be used as endpoints for clinical trials and their regulatory framework 🔥
Exciting times ahead! 🔜
#CTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
tobias-b-huber.bsky.social
Laura Mariani brilliantly discussed how biomarkers can be used as endpoints for clinical trials and their regulatory framework 🔥
Exciting times ahead! 🔜
#CTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
tobias-b-huber.bsky.social
ISGD 🤝 Qualified Health
The first AI-enabled research network!
The future is here.
We are the doers.
tobias-b-huber.bsky.social utmbhealth.bsky.social
#CTS2026 #ISGD #GlomerularDisease #ClinicalTrials #AI #NephTwitter #Nephrology
ISGD 🤝 Qualified Health
The first AI-enabled research network!
The future is here.
We are the doers.
tobias-b-huber.bsky.social utmbhealth.bsky.social
#CTS2026 #ISGD #GlomerularDisease #ClinicalTrials #AI #NephTwitter #Nephrology
Our author is @ManoleaA (nephrology resident)
Our topic: Early BK Polyomavirus–Specific Immunity and Viral Clearance
🔗https://www.sciencedirect.com/science/article/pii/S2468024926032961
#MedTwitter #nephtwitter @ISNkidneycare #XTwitter
Our author is @ManoleaA (nephrology resident)
Our topic: Early BK Polyomavirus–Specific Immunity and Viral Clearance
🔗https://www.sciencedirect.com/science/article/pii/S2468024926032961
#MedTwitter #nephtwitter @ISNkidneycare #XTwitter
#NephTwitter #GlomTwitter #MedEd #KidneyHealth #GNin10
#NephTwitter #GlomTwitter #MedEd #KidneyHealth #GNin10
🔬 Editor's Pick from New England Journal of Medicine
Listen / Read or Share with a colleague 👇
audioscholar.cc/feed/nephrology?w=2026-W43
#NephTwitter #FOAMed
🔬 Editor's Pick from New England Journal of Medicine
Listen / Read or Share with a colleague 👇
audioscholar.cc/feed/nephrology?w=2026-W43
#NephTwitter #FOAMed
🆕 Hey #NephTwitter!
Welcome to a new #tweetorial brought to you by @KIReports!
🫘 Can artificial intelligence improve risk prediction in IgA nephropathy?
🔬 Let's explore how pathomics could reshape kidney biopsy interpretation!
🆕 Hey #NephTwitter!
Welcome to a new #tweetorial brought to you by @KIReports!
🫘 Can artificial intelligence improve risk prediction in IgA nephropathy?
🔬 Let's explore how pathomics could reshape kidney biopsy interpretation!
1/
Hey #NephTwitter!
Welcome to a 🆕 #tweetorial #xtorial brought to you by @KIReports @divyaveerssneph.bsky.social
1/
Hey #NephTwitter!
Welcome to a 🆕 #tweetorial #xtorial brought to you by @KIReports @divyaveerssneph.bsky.social
Our author is @divyaveerssneph.bsky.social
Our topic: Characterization of Patient-Reported Loin Pain in IgAN
doi.org/10.1016/j.ek...
#MedTwitter #nephtwitter @ISNkidneycare #XTwitter
@divyaveerssneph.bsky.social
Our author is @divyaveerssneph.bsky.social
Our topic: Characterization of Patient-Reported Loin Pain in IgAN
doi.org/10.1016/j.ek...
#MedTwitter #nephtwitter @ISNkidneycare #XTwitter
@divyaveerssneph.bsky.social
#NephJC #TenPostNephJC.
#NephTwitter
Patient outcomes are better with transplant vs dialysis.
Is this always true?
What about high-risk donors (expanded criteria donor-ECD) or recipients (elderly with DM or CVD)?
Read the article 👇
link to article on pubmed.ncbi.nlm.nih.gov/42759976/
#NephJC #TenPostNephJC.
#NephTwitter
Patient outcomes are better with transplant vs dialysis.
Is this always true?
What about high-risk donors (expanded criteria donor-ECD) or recipients (elderly with DM or CVD)?
Read the article 👇
link to article on pubmed.ncbi.nlm.nih.gov/42759976/
#ISGD #ClinicalTrials #Nephrology #GlomerularDisease #ESPN2026 #PediatricNephrology #CTB #nephtwitter
#ISGD #ClinicalTrials #Nephrology #GlomerularDisease #ESPN2026 #PediatricNephrology #CTB #nephtwitter
Welcome to a 🆕 #tweetorial #xtorial brought to you by @KIReports
Welcome to a 🆕 #tweetorial #xtorial brought to you by @KIReports
Our topic: 10-year trends in Heart Failure Among Patients with Dialysis and Nondialysis CKD
🔗 www.kireports.org/article/S246...
#MedTwitter #nephtwitter @ISNkidneycare #XTwitter
Our topic: 10-year trends in Heart Failure Among Patients with Dialysis and Nondialysis CKD
🔗 www.kireports.org/article/S246...
#MedTwitter #nephtwitter @ISNkidneycare #XTwitter
🔬 Editor's Pick from Clinical Journal of the American Society of Nephrology
Listen / Read or Share with a colleague 👇
audioscholar.cc/feed/nephrology
#NephTwitter #FOAMed
🔬 Editor's Pick from Clinical Journal of the American Society of Nephrology
Listen / Read or Share with a colleague 👇
audioscholar.cc/feed/nephrology
#NephTwitter #FOAMed
Question 2
#NephJC #NephTwitter
Q: Can MCD & FSGS receive similar steroid taper regimens?
A: Probably not! We need a more adequately powered trial to answer this, especially with FSGS which remains more treatment resistant & steroid resistance may be disease defining
Question 2
#NephJC #NephTwitter
Q: Can MCD & FSGS receive similar steroid taper regimens?
A: Probably not! We need a more adequately powered trial to answer this, especially with FSGS which remains more treatment resistant & steroid resistance may be disease defining